Covid-19 vaccines and treatments: we must have raw data, now

Data should be fully and immediately available for public scrutiny In the pages of The BMJ a decade ago, in the middle of a different pandemic, it came to light that governments around the world had spent billions stockpiling antivirals for influenza that had not been shown to reduce the risk of complications, hospital admissions,… Continue reading Covid-19 vaccines and treatments: we must have raw data, now

Persistence of clinically relevant levels of SARS-CoV2 envelope gene subgenomic RNAs in non-immunocompromised individuals

Highlights•SARS-CoV-2 activity is difficult to assess with conventional PCR assays.•Subgenomic RNA (sgRNA) may be a better proxy for infectivity.•Over 10% of COVID-19 patients were sgRNA positive beyond a 10-day period.•Long-duration sgRNA-positive patients were clinically unremarkable.•Vulnerable settings may require additional measures to minimize transmission.Abstract ObjectivesThis study aimed to evaluate the associations between COVID-19 severity and active… Continue reading Persistence of clinically relevant levels of SARS-CoV2 envelope gene subgenomic RNAs in non-immunocompromised individuals

Maternal COVID-19 Vaccination and Its Potential Impact on Fetal and Neonatal Development

Vaccines have been developed at “warp speed” to combat the COVID-19 pandemic caused by the SARS-CoV-2 coronavirus. Although they are considered the best approach for preventing mortality, when assessing the safety of these vaccines, pregnant women have not been included in clinical trials. Thus, vaccine safety for this demographic, as well as for the developing… Continue reading Maternal COVID-19 Vaccination and Its Potential Impact on Fetal and Neonatal Development

COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status andPrevious COVID-19 Diagnosis — California and New York, May–November 2021

During the study period, COVID-19 incidence inboth states was highest among unvaccinated persons without aprevious COVID-19 diagnosis compared with that among theother three groups. During the week beginning May 30, 2021,compared with COVID-19 case rates among unvaccinated persons without a previous COVID-19 diagnosis, COVID-19case rates were 19.9-fold (California) and 18.4-fold (New York)lower among vaccinated persons… Continue reading COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status andPrevious COVID-19 Diagnosis — California and New York, May–November 2021

Short- vs Standard-Course Outpatient Antibiotic Therapy for Community-Acquired Pneumonia in ChildrenThe SCOUT-CAP Randomized Clinical Trial

Childhood community-acquired pneumonia (CAP) is usually treated with 10 days of antibiotics. Shorter courses may be effective with fewer adverse effects and decreased potential for antibiotic resistance. Objective To compare a short (5-day) vs standard (10-day) antibiotic treatment strategy for CAP in young children. Design, Setting, and Participants Randomized double-blind placebo-controlled clinical trial in outpatient… Continue reading Short- vs Standard-Course Outpatient Antibiotic Therapy for Community-Acquired Pneumonia in ChildrenThe SCOUT-CAP Randomized Clinical Trial

Intranasal ketamine for acute cluster headache attacks—Results from a proof-of-concept open-label trial

ObjectiveTo investigate the safety and efficacy of intranasal ketamine for the treatment of a single cluster headache (CH) attack. BackgroundAcute treatment options for patients with CH who have an insufficient response to oxygen and triptans are limited. Intranasal ketamine has anecdotally been successful in treating a CH attack. MethodsWe conducted an open-label pilot study enrolling… Continue reading Intranasal ketamine for acute cluster headache attacks—Results from a proof-of-concept open-label trial

Expected Viscosity After COVID-19 Vaccination, Hyperviscosity and Previous COVID-19

COVID-19 vaccine is the hope for containment of disease outbreak. The post vaccination adverse effect is an important consideration. The clot after vaccination is an emerging important clinical problem in some vaccine recipients.1 The cause of post vaccination blood clot is not known. It is proposed that the problem might be due to immunopathological process.2… Continue reading Expected Viscosity After COVID-19 Vaccination, Hyperviscosity and Previous COVID-19

First time detection of the vaccine spike protein in a person who died after vaccination against Covid-19.

The suspicion that the spike protein formed in the body as a result of the "vaccination" against Covid-19 could be responsible for the pathologically observed inflammations and lesions of vessels has now been confirmed immunohistologically for the first time. The pathologists Prof. Dr. Arne Burkhardt and Prof. Dr. Walter Lang and their team have succeeded… Continue reading First time detection of the vaccine spike protein in a person who died after vaccination against Covid-19.

Vitamin D supplementation and prevention of cardiovascular disease and cancer in the Finnish Vitamin D Trial—a randomized controlled trial

Vitamin D insufficiency is associated with risk of cardiovascular diseases (CVD) and cancer in observational studies, but evidence for benefits with vitamin D supplementation is limited. ObjectivesTo investigate the effects of vitamin D3 supplementation on CVD and cancer incidence. DesignThe study was a 5-year randomized placebo-controlled trial among 2495 male participants ≥ 60 years and… Continue reading Vitamin D supplementation and prevention of cardiovascular disease and cancer in the Finnish Vitamin D Trial—a randomized controlled trial